Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC
This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID‐19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361293/ https://www.ncbi.nlm.nih.gov/pubmed/32583525 http://dx.doi.org/10.1111/hepr.13541 |
_version_ | 1783559362110816256 |
---|---|
author | Kudo, Masatoshi Kurosaki, Masayuki Ikeda, Masafumi Aikata, Hiroshi Hiraoka, Atsushi Torimura, Takuji Sakamoto, Naoya |
author_facet | Kudo, Masatoshi Kurosaki, Masayuki Ikeda, Masafumi Aikata, Hiroshi Hiraoka, Atsushi Torimura, Takuji Sakamoto, Naoya |
author_sort | Kudo, Masatoshi |
collection | PubMed |
description | This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID‐19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID‐19 and the availability of resources, including personal protective equipment and inpatient beds). In addition, models suggest that the second and third waves of COVID‐19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2–3 years). This guide should serve as a good reference for best practices in the management of HCC, which is in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID‐19 infections. |
format | Online Article Text |
id | pubmed-7361293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73612932020-07-15 Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC Kudo, Masatoshi Kurosaki, Masayuki Ikeda, Masafumi Aikata, Hiroshi Hiraoka, Atsushi Torimura, Takuji Sakamoto, Naoya Hepatol Res Special Report This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID‐19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID‐19 and the availability of resources, including personal protective equipment and inpatient beds). In addition, models suggest that the second and third waves of COVID‐19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2–3 years). This guide should serve as a good reference for best practices in the management of HCC, which is in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID‐19 infections. John Wiley and Sons Inc. 2020-07-20 2020-09 /pmc/articles/PMC7361293/ /pubmed/32583525 http://dx.doi.org/10.1111/hepr.13541 Text en © 2020 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Special Report Kudo, Masatoshi Kurosaki, Masayuki Ikeda, Masafumi Aikata, Hiroshi Hiraoka, Atsushi Torimura, Takuji Sakamoto, Naoya Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC |
title | Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC |
title_full | Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC |
title_fullStr | Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC |
title_full_unstemmed | Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC |
title_short | Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC |
title_sort | treatment of hepatocellular carcinoma during the covid‐19 outbreak: the working group report of jamtt‐hcc |
topic | Special Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361293/ https://www.ncbi.nlm.nih.gov/pubmed/32583525 http://dx.doi.org/10.1111/hepr.13541 |
work_keys_str_mv | AT kudomasatoshi treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc AT kurosakimasayuki treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc AT ikedamasafumi treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc AT aikatahiroshi treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc AT hiraokaatsushi treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc AT torimuratakuji treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc AT sakamotonaoya treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc |